C.R. Bard Prevails Again in Stent Graft Patent War With W. L. Gore & Associates, Inc.

Published: Oct 18, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

A federal judge upholds C.R. Bard's patent infringement win over W.L. Gore & Assoc. in their decades-long war over stent graft technology, setting Bard up to collect some $800 million in damages, royalties and legal fees. C.R. Bard (NYSE:BCR) won another round in its decades-long patent infringement war with W.L. Gore & Assoc. over stent graft technology after a federal judge found yesterday that Gore willfully infringed the patent. An appeals court last year tasked Judge Mary Murguia of the U.S. District Court for Arizona with reviewing her prior finding of willfulness.

Help employers find you! Check out all the jobs and post your resume.

Back to news